Pulse Biosciences Q3 net loss widened 19% year over year to $23.05 million
PLSE•Pulse Biosciences’ third-quarter 2026 GAAP net loss widened 19% year over year to $23.05 million. Revenue rose to $395,000, and cash, cash equivalents and marketable securities reached $189.2 million at September 30.
1. Quarterly results
Pulse Biosciences reported third-quarter 2026 GAAP costs and expenses of $24.69 million, up 21% year over year, and revenue of $395,000. Cash, cash equivalents and marketable securities climbed 86% from June 30 to $189.2 million at September 30; NANOPULSE-AF completed enrollment with 169 evaluable patients, three months ahead of plan.
